Resistance, not tachyphylaxis or tolerance

British Journal of Ophthalmology

Volumn 96, Issue 8, 2012, Pages 1153-1154

  Arjamaa, Olli ^a   Minn, Heikki ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DESENSITIZATION; DRUG APPROVAL; DRUG PREFERENCE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TACHYPHYLAXIS; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; TACHYPHYLAXIS;

EID: 84864849235     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-301823     Document Type: Letter

References (7)

1. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012;96:1-2.
2. Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012;96:21-3.
3. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20.
4. Dempke WC, Heinemann V. Resistance to EGF-R (erB-1) and VEGF-R modulating agents. Eur J Cancer 2009;45:1117-28.
5. Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012;118:3455-3467.
6. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27.
7. Tamaskar I, Dhillon J, Pili R. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 2011;9:101-10.